Drug Profile
Research programme: caspase-3 inhibitors - AstraZeneca
Latest Information Update: 18 Jan 2007
Price :
$50
*
At a glance
- Originator AstraZeneca Pharmaceuticals
- Class
- Mechanism of Action Apoptosis inhibitors; Caspase-3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Neurological disorders
Most Recent Events
- 31 Jan 2003 Preclinical trials in Neurological disorders (Prevention) in USA (unspecified route)